Regeneron Pharmaceuticals, Inc.
Close on Nov 19, 2026Market cap $95.52BP/E 20.4Yield –
Regeneron Pharmaceuticals Total Collaboration Revenue by Quarter
Total Collaboration Revenue (Sanofi, Bayer, Roche & Other) ($M) ($M)
Regeneron Pharmaceuticals Total Collaboration Revenue: $3,001M in Q3 2026, up 52.4% from a year earlier. That is the highest of the 33 quarters on record here.
Where the Q3 2026 figure comes from
“Table 4 (FY2026Q3): Total collaboration revenue | $ | 3,000.5 | $ | 1,968.4 | $ | 7,355.2 | $ | 5,360.3”
Source: Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Table 4.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Total Collaboration Revenue ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-collab-total
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?